Helsinn Achieves Carbon Neutrality

Helsinn Achieves Carbon Neutrality

Lugano, Switzerland, December 6, 2021 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, today announces that it has achieved carbon neutrality for …

Read More

Helsinn Achieves Carbon Neutrality

Helsinn Achieves Carbon Neutrality

Lugano, Switzerland, December 6, 2021 Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, today announces that it has achieved carbon neutrality for

Read More

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

First and only neutralizing antibody therapy for this age group

SHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States

Read More